Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 18, 2017
Pharmacy Choice - Pharmaceutical News - Transcatheter Device By Medtronic plc. Ordinary Shares (NYSE:MDT) Gets FDA Nod - August 18, 2017

Pharmacy News Article

 3/17/17 - Transcatheter Device By Medtronic plc. Ordinary Shares (NYSE:MDT) Gets FDA Nod

The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic plc. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug Administration. The device is implanted in patients in cases where surgical pulmonary heart valves are not working. This transcatheter pulmonary valve is the first of its kind to be approved in the United States.

Melody TPV is uniquely designed for use in the pulmonic position and is thus well suited for implantation in failed surgical pulmonary heart valves. This approval further demonstrates our commitment to improving treatment options for congenital heart disease?, Rhonda Robb, a general manager and vice president at a Medtronic subsidiary said.

Open-heart surgery

In cases where a surgical valve has degenerated over the course of time, a replacement is normally required and this usually involves open-heart surgery. But with the Melody Transcatheter Pulmonary Valve, patients now have an option that is minimally invasive. In the course of the procedure to place the Melody TPV inside the surgical pulmonary valve that is failing, a delivery catheter which has been designed specifically for this purpose is utilized.

As the pioneering transcatheter heart valve in the world, this device has been implanted in patients numbering more than 10,000 across the globe. This device first got the CE Mark more than a decade ago during which time numerous trials have proven the efficacy of the device in delaying open heart surgery with a view to replacing the broken pulmonary heart valve. It was first launched in the United States in 2010 after getting the approval of the Food and Drug Administration.

Global reach

With the transcatheter valve market expected to be worth $8.62 billion globally, Medtronic is well placed to take advantage. Besides the Melody TPV, Medtronic has a wide range of devices and technologies that are used in treating cardiac arrhythmias and cardiovascular diseases. The Dublin, Ireland-based medical technology firm is among the largest in the world in its space. It has a presence in over 160 countries and employs over 88,000 people across the globe.

In Thursday's trading session, shares of Medtronic plc fell by 1.76% to close the day at $81.83 a share.

The post Transcatheter Device By Medtronic plc. Ordinary Shares (NYSE:MDT) Gets FDA Nod appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Aug 21: An Integrative Approach to Managing Arthritis
Aug 22: Men's Health
Aug 23: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Aug 24: Treatment of Parkinson's Disease and Comorbid Conditions
Aug 25: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415